Ashurst advises Perspix Biotech on market entry in AI-driven drug

Ashurst advised Perspix Biotech GmbH, a biopharma company committed to create efficient next-generation biotherapeutics, on its market entry.

Frankfurt-based Perspix Biotech was founded in 2021 and is active in the field of pre-clinical drug development. Perspix seeks to deploy a novel and versatile biotechnology platform generating a constant stream of multi-specific antibodies for immuno-oncology. Ashurst advised, in particular, on corporate, employment, finance and IP-related matters and assisted Perspix in structuring an end-to-end automation of lab processes that will generate multi-dimensional data sets of unprecedented quality. These data sets form the basis for the training of dedicated AI engines to solve complex challenges in biological drug design.

The Ashurst team was led by partner Dr Gerrit Clasen and counsel Martina Rothe. They were assisted by senior associate Quynh Anh Le (all Corporate/M&A).